New IVIG aims to slash infection risk for immune-deficient patients
Disease control
Not yet recruiting
This study tests a new medicine called Boya IVIG in 50 people with primary immunodeficiency (CVID or XLA), a condition where the body can't fight infections well. Participants get the drug every 21 or 28 days for a year to see if it keeps serious bacterial infections below one pe…
Phase: PHASE3 • Sponsor: Azidus Brasil • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC